214 POSTER AP5346 (ProLindacTM), a pH-dependent polymer-vectorized DACH platinum, is active in borderline potentially platinum-sensitive ovarian cancer (OC) patients: results from an ongoing Phase I/II trial

Joly, Fabien; Madroszyk, Anne; Floquet, Anne; Gédouin, D; Bourdel, Fabrice; Campone, Mario

doi:10.1016/s1359-6349(08)72146-3

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…218 This result was comparable to single agent oxaliplatin trialled in a less heavily pre-treated population. 217 All patients experienced at least one side effect although most were mild at grade 1-2, and there were no signs of acute neurotoxicity.…”

mentioning

confidence: 69%

“…217, 218 Treatment was again well tolerated and clinically-meaningful disease stabilisation was achieved in 42% of all patients and 66% of patients who received the highest dose (560 mg m -2 week -1 over three weeks or 1100 mg m -2 week -1 over two weeks). 218 This result was comparable to single agent oxaliplatin trialled in a less heavily pre-treated population.…”

mentioning

confidence: 93%

See 1 more Smart Citation

The status of platinum anticancer drugs in the clinic and in clinical trials

et al. 2010

View full text Add to dashboard Cite

Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for\ud the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and\ud melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and\ud intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered\ud clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing\ud approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual\ud nations. During this time there have been more failures than successes with the development of 14 drugs\ud being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial\ud (satraplatin, picoplatin, LipoplatinTM and ProLindacTM). No new small molecule platinum drug has\ud entered clinical trials since 1999 which is representative of a shift in focus away from drug design and\ud towards drug delivery in the last decade. In this perspective article we update the status of platinum\ud anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued\ud during clinical trials, and discuss the results in the context of where we believe the field will develop over\ud the next decade

show abstract

mentioning

confidence: 69%

mentioning

confidence: 93%

The status of platinum anticancer drugs in the clinic and in clinical trials

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Considering the long half-life of ProLindac observed in patients, weekly doses were considered unsuitable and dosage was reduced to a two-hour i.v. infusion every two or three weeks [190]. This treatment was also well tolerated and resulted in the disease stabilization in a significant number of patients [188,190].…”

Section: Platinum Drug Delivery Using Nanocarriersmentioning

confidence: 99%

“…infusion every two or three weeks [190]. This treatment was also well tolerated and resulted in the disease stabilization in a significant number of patients [188,190]. The side effects experienced by patients were mild at grades 1–2, and without any signs of acute neurotoxicity [188].…”

Section: Platinum Drug Delivery Using Nanocarriersmentioning

confidence: 99%

Nanocarriers for delivery of platinum anticancer drugs

Oberoi¹,

Nukolova²,

Kabanov³

et al. 2013

Advanced Drug Delivery Reviews

353

309

View full text Add to dashboard Cite

Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum–polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.

show abstract

“…Less success was found with HPMA conjugates of paclitaxel or camptothecin [4. 5], however encouraging results have been found from Platinum-HPMA chelates [8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Increasing the Tumoricidal Activity of Daunomycin-pHPMA Conjugates Using Vitamin B12 as a Targeting Agent

Russell‐Jones¹,

McTavish²,

McEwan³

et al. 2012

J. Can. Res. Updates

View full text Add to dashboard Cite

Many different types of tumour have previously been shown to over-express cell-surface receptors involved in the uptake of Vitamin B12 (VB12). We have examined the potential of using VB12 as a targeting agent for the delivery of pHPMA-conjugated daunomycin in four murine tumour models. VB12-targeted-duanomycin-HPMA conjugates were found to increase both the number of survivors and the survival time of tumour-bearing mice. The data indicate that VB12 may be highly effective in enhancing the efficacy of polymer-bound cytotoxins, particularly in those tumours that overexpress receptors involved in vitamin B12 uptake.

show abstract

214 POSTER AP5346 (ProLindacTM), a pH-dependent polymer-vectorized DACH platinum, is active in borderline potentially platinum-sensitive ovarian cancer (OC) patients: results from an ongoing Phase I/II trial

Cited by 3 publications

References 0 publications

The status of platinum anticancer drugs in the clinic and in clinical trials

The status of platinum anticancer drugs in the clinic and in clinical trials

Nanocarriers for delivery of platinum anticancer drugs

Increasing the Tumoricidal Activity of Daunomycin-pHPMA Conjugates Using Vitamin B12 as a Targeting Agent

Contact Info

Product

Resources

About